Anti-SARS-CoV-2 RBD (BA.5) Human IgM ELISA Kit

Catalog No.

KAV00303

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative indirect enzyme immunoassay technique. Recombinant SARS-CoV-2 RBD (BA.5) has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any Anti-SARS-CoV-2 RBD (BA.5) Human IgM present is bound by the immobilized protein. After washing away any unbound substances, a biotin-labeled Mouse Anti-Human IgM antibody is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Anti-SARS-CoV-2 RBD (BA.5) Human IgM bound in the initial step. The color development is stopped and the intensity of the color is measured.

Specificity

Anti-SARS-CoV-2 RBD (BA.5) Human IgM Antibody

Applications

Used for the quantitative determination of Anti-SARS-CoV-2 RBD (BA.5) Human IgM concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

93.75 - 6,000 ng/mL

Sensitivity

22.06 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <10%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <15%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	3734.3	845.0	213.1	4080.8	993.0	222.0
Standard deviation	130.2	26.7	19.0	289.7	51.1	26.3
CV (%)	3.5	3.2	8.9	7.1	5.1	11.8

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Characterization of SARS-CoV-2-specific humoral immunity and associated factors in the healthy population post-vaccination., PMID:38103966

Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study., PMID:37437051

A Versatile Biomimic Nanotemplating Fluidic Assay for Multiplex Quantitative Monitoring of Viral Respiratory Infections and Immune Responses in Saliva and Blood., PMID:36253095

SARS-CoV-2 Seroprevalence Study in Pediatric Patients and Health Care Workers Using Multiplex Antibody Immunoassays., PMID:36146844

Evaluation of Performance of Detection of Immunoglobulin G and Immunoglobulin M Antibody Against Spike Protein of SARS-CoV-2 by a Rapid Kit in a Real-Life Hospital Setting., PMID:35558113

Timeline of SARS-CoV-2 Spread in Italy: Results from an Independent Serological Retesting., PMID:35062265

Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay., PMID:34136587

COVID-19 in Russia: Clinical and Immunological Features of the First-Wave Patients., PMID:33959390

Application of newly developed SARS-CoV2 serology test along with real-time PCR for early detection in health care workers and on-time plasma donation., PMID:33869895

Document Download

Anti-SARS-CoV-2 RBD (BA.5) Human IgM ELISA Kit.pdf